Evusheld receives Health Canada approval for treatment of mild to moderate Covid-19
AstraZeneca's Evusheld (tixagevimab and cilgavimab), a long-acting antibody combination has received a Notice of Compliance from Health Canada for the treatment of mild to moderate COVID-19 in adults and adolescents ( greater than 12 years of age weighing at least 40 kg)
This approval follows AstraZeneca’s announcement in April that Evusheld had been approved as a preventative treatment for COVID-19 and is already available across Canada.
“Certain Canadians continue to be vulnerable to poor outcomes from COVID-19 and having a new treatment option in our arsenal, particularly one that is given as a single dose, is especially welcome news as we move into the winter months when we expect case counts to rise,” said Dr. Zain Chagla, Associate Professor, Medicine, Faculty of Health Sciences, McMaster University. “Studies show long-acting antibodies can play an effective role in both treatment and prevention of COVID-19. Evusheld has already made an impact preventing infection in vulnerable populations, such as the immune-compromised, and now has the potential to play an important role in COVID-19 treatment, making sure that high risk patients have even more access to therapeutic options.”
The approval by Health Canada was based on results from the TACKLE Phase III treatment trial, which demonstrated reduced risk of severe COVID-19 or death in high-risk patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins